


Fact Sheet: Reduced Coinsurance for Certain Part B Rebatable Drugs Under the Medicare Prescription Drug Inflation Rebate Program



Applicable October 1 – December 31, 2024

President Biden’s historic Inflation Reduction Act requires drug companies to pay rebates to Medicare when prescription drug prices increase faster than the rate of inflation for certain drugs furnished to people with Medicare. This new inflation rebate applies to Medicare Part B rebatable drugs, which are single source drugs and biological products, including certain biosimilar biological products, beginning January 1, 2023.

The federal government intends to invoice drug manufacturers for 2023 and 2024 Part B inflation rebates no later than fall 2025. The rebates will be deposited into the Medicare Trust Fund. In addition, beginning April 1, 2023, people with Medicare may see lower out-of-pocket costs for certain Part B drugs and biologicals with prices that have increased faster than the rate of inflation. For these drugs and biologicals, the beneficiary coinsurance will be 20% of the inflation-adjusted payment amount, which will be less than what the beneficiary would pay in coinsurance otherwise.

CMS posts payment information each quarter for separately payable Part B drugs, including the Part B rebatable drugs subject to the coinsurance adjustments, in the Medicare Part B Quarterly Sales Pricing (ASP) files, which are publicly available on [CMS.gov](https://www.cms.gov). The October 2024 ASP public files will also include the coinsurance adjustments for certain Part B rebatable drugs as required by the Inflation Reduction Act. The Part B drugs impacted by a coinsurance adjustment may change quarterly.¹

For the time period of October 1 – December 31, 54 Part B rebatable drugs have an adjusted coinsurance rate based on the inflation-adjusted payment amount. People with Traditional Medicare and Medicare Advantage who use these drugs may, depending on other health coverage they may have, pay a reduced amount for their coinsurance during this specific quarter. For the quarter, October 1 – December 31, people with Medicare may experience coinsurance amounts that are lower than what they would have paid before the new law passed by as much as \$1 – \$3,854 per day.

CMS’ normal procedure is to release the ASP public files several weeks before the quarter they will go into effect so the public can review and notify CMS of any potential discrepancies. From time to time, ASP public files need to be corrected or updated, generally referred to as a restatement, based on feedback received after the files are published. If CMS receives feedback that necessitates updates to this list of drugs with adjusted coinsurance amounts, CMS will update the list. The October 1 – December 31, 2024 files may be subject to updates either before the start of the quarter or after in the event updated data becomes available.

Below is the list of drugs with adjusted coinsurance amounts for the quarter October 1 – December 31, 2024. Learn more about the [Medicare Prescription Drug Inflation Rebate Program](#) including a fact sheet on the Part B rebatable drug coinsurance reduction.

¹Adjusted coinsurance and payment limits for certain drugs and biologicals used predominantly in the hospital outpatient setting are only listed in the Hospital Outpatient Prospective Payment System (OPPS) pricing files, which can be found at [OPPS Addendum B](#). We recommend reviewing these Addenda, as well as the [ASP Pricing Files](#).

HCPCS Code	Short Description	Inflation-Adjusted Coinsurance Percentage (Normally 20.000%)
Q2055	Abecma	19.40%
J9042	Adcetris	18.91%
J8655	Akynzeo Capsule	18.95%
J7504	Atgam	14.27%
J3145	Aveed	19.30%
J0558	Bicillin C-R	14.79%
J0561	Bicillin L-A	14.95%
J9039	Blinicyto	19.26%
Q2054	Breyanzi	19.33%
J2329	Briumvi	19.97%
Q2056	Carvykti	19.79%
J0703	Cefepime (B. Braun)	9.11%
J2850	Chirhostim*	19.59%
J1833	Cresemba*	19.89%
J0584	Crysvita	18.84%
J9348	Danyelza	19.58%
J7503	Envarsus XR	19.93%
J3111	Evenity	19.97%
J9307	Folotyng	19.90%
J1456	Fosaprepitant	3.90%
J1645	Fragmin	12.03%
J9394	Fulvestrant (Fresenius)	12.48%
J9331	Fyarro	19.85%
J9196	Gemcitabine (Accord)	11.18%
J1670	Hypertet	19.94%
J9325	Imlygic	19.26%

HCPCS	Drug name	Inflation-Adjusted Coinsurance Percentage (Normally 20.000%)
J2425	Kepivance*	16.88%
J2507	Krystexxa	19.97%
Q2042	Kymriah	19.27%
J9047	Kyprolis	19.58%
J2820	Leukine	19.69%
J2021	Linezolid (Pfizer)	12.01%
J1950	Lupron Depot-Ped	19.38%
J2184	Meropenem (B. Braun)	9.34%
J2265	Minocin*	18.54%
J0283	Nexterone (Baxter)	11.76%
J9268	Nipent	18.59%
J2796	Nplate	19.52%
J9266	Oncaspar	19.08%
J9177	Padcev	18.96%
J1640	Panhematin	19.69%
J0897	Prolia	18.65%
J9061	Rybrevant	19.89%
J9021	Rylaze	19.99%
J2502	Signifor LAR*	17.56%
C9482	Sotalol (Altathera)*	18.47%
J2860	Sylvant	18.61%
J3250	Tigan	19.05%
J9273	Tivdak	19.47%
J9303	Vectibix	19.35%
J0775	Xiaflex	18.33%
Q2041	Yescarta	19.37%
J0695	Zerbaxa	19.33%
J9202	Zoladex	18.89%

Notes:

Per the revised guidance for Medicare Part B Drug inflation rebates, if a single-source drug (e.g., a 505(b)(2) product) was previously billed as part of a grouped HCPCS code during the benchmark quarter, then the benchmark payment amount should be the payment limit for the grouped HCPCS code during the benchmark quarter. Per the guidance, we compared the benchmark payment limit for the grouped HCPCS code to the payment limit for the single-source HCPCS code in the October 2024 quarter to determine whether the payment amount increased faster than inflation. If so, the product is eligible for reduced coinsurance. Additional information can be found at [**Medicare Part B Inflation Rebate Program Revised Guidance \(PDF\)**](#).

*These codes are Outpatient Prospective Payment System (OPPS) only products and can be found in Addendum B of the OPPS website. Actual savings may vary depending on the location of the service.